Host biomarkers for monitoring therapeutic response in extrapulmonary tuberculosis. (June 2021)

• Record Type: Journal Article
• Authors: Ambreen, Atiqa; Khaliq, Aasia; Naqvi, Syed Zeeshan Haider; Tahir, Amna; Mustafa, Manal; Chaudhary, Safee Ullah; Mirza, Shaper; Mustafa, Tehmina
• Is Part Of: Cytokine. Volume 142(2021)
• Publication Date: 2021-06
• Subjects: Extra-pulmonary tuberculosis -- Lymphadenitis -- Pleuritis -- Response to treatment -- Inflammatory biomarkers; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2021.155499
• Languages: English
• ISSNs: 1043-4666

Abstract

Abstract: Purpose: The aim of this study was to explore the utility of inflammatory biomarkers in the peripheral blood to predict response to treatment in extrapulmonary tuberculosis (EPTB). Methods: A Luminex xMAP-based multiplex immunoassay was used to measure 40 inflammatory biomarkers in un-stimulated plasma of 91 EPTB patients (48 lymphadenitis, and 43 pleuritis) before and at 2 and 6 months of treatment. Results: Overall a significant change was observed in 28 inflammatory biomarkers with treatment in EPTB patients. However, MIG/CXCL9, IP-10/CXCL10, and CCL23 decreased in all patients' groups with successful treatment at both time points. At 2 months, 29/64 (45%) patients responded partially while 35/64 (55%) showed complete regress. Among good responders, a higher number of biomarkers (16/40) reduced significantly as compared to partial responders (1/40). Almost half (14/29) of partial responders required longer treatment than 6 months to achieve satisfactory response. The levels of MIG, IP-10, MIF, CCL22 and CCL23 reduced significantly among 80, 74, 60, 71, 51% good responders, as compared to 52, 52, 52, 59, 52% partial responders, respectively. A biosignature, defined by a significant decrease in any one of these five biomarkers, corresponded with satisfactory response to treatment in 97% patients at 2 month and 99% patients at 6 months of treatment. Conclusion: Change in inflammatory biomarkers correlates with treatment success. A five biomarker biosignature (MIG, IP-10, MIF, CCL22 and CCL23) could be used as an indicator of treatment success.